Greg Zante, Chief Financial Officer, on July 28, 2026, sold 21,217 shares in Viking Therapeutics (VKTX) for $710,141. Following the Form 4 filing with the SEC, Zante has control over a total of 212,204 common shares of the company, with 212,204 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1607678/000119312526324447/xslF345X05/ownership.xml